March 22, 2019
1 min read
Save

Disorganization of retinal inner layers may be biomarker for macular surgery outcomes

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Matias Iglicki

FORT LAUDERDALE, Fla. — Patients with idiopathic epiretinal membranes and severe disorganization of retinal inner layers did not experience significant improvements in vision after undergoing pars plana vitrectomy with epiretinal membrane peeling, according to a speaker here.

“DRIL (disorganization of retinal inner layers) severity strongly correlates with functional and anatomical measures in patients with idiopathic ERM (epiretinal membrane), and DRIL can be used as a biomarker to predict outcomes after surgery,” Matias Iglicki, MD, said at the Retina World Congress.

Iglicki presented the findings of the Disorganization of Retinal Inner Layers as a Biomarker for Idiopathic Epiretinal Membrane after Macular Surgery (DREAM) study. The researchers evaluated the extent of DRIL and its predictive value for visual outcomes after macular surgery. The main outcome measures were the presence and severity of DRIL at baseline, anatomic and visual outcomes, and the correlation of DRIL and baseline characteristics and outcome measures, he said.

Ninety patients with idiopathic ERM underwent pars plana vitrectomy and membrane peeling and were followed for 12 months postoperatively. At 12 months, patients with severe DRIL did not gain any visual or anatomical results. The same was found for central macular thickness, Iglicki said. – by Robert Linnehan

 

Reference:

Zur D. Disorganization of Retinal Inner Layers as a Biomarker for Idiopathic Epiretinal Membrane after Macular Surgery: The DREAM Study. Presented at: Retina World Congress; March 21 to 24, 2019; Fort Lauderdale, Fla.

Disclosure: Iglicki reports he is a consultant for Allergan, Bayer and Novartis.